BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma
about
Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cellsMLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.Expression of Apoptosis-regulating Proteins Bcl-2 and Bax in Lymph Node Aspirates from Dogs with Lymphoma.Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma.Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.Flow cytometric sorting coupled with exon capture sequencing identifies somatic mutations in archival lymphoma tissues.Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.XIII. Molecular pathogenesis of transformed lymphomas.Bcl-2 proteins in development, health, and disease of the hematopoietic system.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Recommendations for Clinical Trial Development in Follicular Lymphoma.Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size.BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab.High-risk follicular lymphomas harbour more somatic mutations including those in the AID-motifNew developments in the pathology of malignant lymphoma: a review of the literature published from October 2014-December 2014.Getting a GRP on histone deacetylase inhibitor selectivity.Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations.Transformed follicular lymphoma.Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.Unmet needs in the first-line treatment of follicular lymphoma.MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma.B-cell lymphomas with discordance between pathological features and clinical behavior.
P2860
Q33808800-2D9083D1-C771-4C12-9D7B-D62C223CDE75Q36751575-E3ACED2C-9D94-4DF6-82EF-5EB570BDE67CQ37020239-4405CD58-DFE8-4D7E-BB7D-A3F97A4704F1Q37220666-220578F3-6C67-438D-B9C4-FB2796199571Q37237891-376AE40A-7751-466E-B11D-EFFE8B8BA98BQ37609908-0AA2D2C0-6BC1-4A28-B85C-116275D95E00Q38372504-90702132-1516-4B4A-8A93-6BDAFE22D6A7Q38398064-D6D64A5D-A423-4EC1-B0D4-F42B74B08611Q38524010-FB814E56-7986-4D98-827C-1DB608B1E629Q38735628-F2717B0A-E742-4084-8D65-F622041E7CEEQ38819164-264F9446-8123-4B62-BA23-74D131482CE2Q39063872-F7A41B63-B25F-4306-9D1B-D874C19825ACQ39221094-DA81D178-EF21-4F1F-A2FC-F8E1B8633694Q39267135-407A74BD-A357-4B68-ADC8-3FF4B63378A3Q39599213-E40322DE-4F4E-4754-AF01-9D8970338410Q40313556-10607C04-D779-44E7-BD0D-B7C8153C54D2Q42630555-EB3E60DD-40C7-47FF-9FF4-5F537EEC498FQ43184380-6ADBF910-2FBC-4281-894D-9DF61122FCD7Q45808456-8749504E-1DEE-402A-B1CF-2DDA64BD0CF1Q46792686-081A41CE-D8B6-48F3-A3F9-09674683F063Q47771789-AFA9C00D-56DE-4BA7-B5F3-DAA05D440D59Q48298180-7595A58F-5959-43A7-ACC6-1DE0FCF116E1Q50099990-31B251DD-CE90-4B4C-8702-2907914BED58Q50710717-7B2B95F2-1E5B-4B8B-A544-C3A7A2A1C117Q51334810-7FB6BA66-31D0-4114-98F8-F2D5627CD167Q52863282-222B5096-7C09-4C59-B8E0-C1C701B4C178
P2860
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
BCL2 mutations are associated ...... urvival in follicular lymphoma
@ast
BCL2 mutations are associated ...... urvival in follicular lymphoma
@en
type
label
BCL2 mutations are associated ...... urvival in follicular lymphoma
@ast
BCL2 mutations are associated ...... urvival in follicular lymphoma
@en
prefLabel
BCL2 mutations are associated ...... urvival in follicular lymphoma
@ast
BCL2 mutations are associated ...... urvival in follicular lymphoma
@en
P2093
P2860
P50
P1433
P1476
BCL2 mutations are associated ...... urvival in follicular lymphoma
@en
P2093
Ahmet Dogan
Amy K Church
Anne J Novak
Cristina Correia
Diane F Jelinek
Grzegorz S Nowakowski
Husheng Ding
James R Cerhan
Judith E Karp
Matthew J Maurer
P2860
P304
P356
10.1182/BLOOD-2014-04-571786
P407
P577
2014-12-01T00:00:00Z